ALSO NOTED: Nexavar OK'd for use against liver cancer; Japan's Olympus to buy Gyrus in $1.9 billion deal;

> Bayer and Onyx Pharmaceuticals got the FDA's nod to market Nexavar to treat liver cancer; the drug already is used against kidney cancer. Report

> Surgical equipment maker Gyrus recommended that its shareholders accept a $1.9 billion cash tender offer from Olympus, the Japanese camera company. Report

> Schering-Plough has wrapped up its acquisition of Organon BioSciences. Report

> Sales of over-the-counter cold meds for kids have fallen sharply since an FDA panel concluded they shouldn't be used in children younger than 6. Report

> India's Plethico Pharma is buying U.S.-based Natrol, a manufacturer and marketer of nutritional products, for $80.7 million. Report

> A Dallas whistleblower has implicated a multitude of surgical suppliers in a Medicare-fraud suit just unsealed in federal court. Report

And Finally... The much talked-about Baby Boomer generation is heading into their 50s--and they're looking to biotechnology to not only to extend their lives, but to make their later years better. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.